Last reviewed · How we verify
NCT05782764
A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom
Phase 4 trial testing To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV). in Lung Squamous Cell Carcinoma in 30 participants. Status unknown.
30 May 2025
Quick facts
| Lead sponsor | Xuzhou Medical University |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 June 2023 |
| Primary completion | 30 May 2025 |
| Estimated completion | 30 May 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
Conditions studied
- Lung Squamous Cell Carcinoma — all drugs for Lung Squamous Cell Carcinoma →
Sponsor
Xuzhou Medical University
Who can join
Adults 18 to 78, any sex, with Lung Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy.
Choi Y, Jung K. · · 2023 · cited 100× · PMID 37907742 · DOI 10.1038/s12276-023-01114-w
Verify or expand the search:
- PubMed search for NCT05782764
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT07275073 — JMT106 Injection in the Treatment of Advanced Solid Tumors · Phase 1 · recruiting
- NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
- NCT06121505 — Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced · Phase 2 · recruiting
- NCT06436040 — Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma · recruiting
- NCT05778253 — The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC · recruiting
Other Xuzhou Medical University trials
Trials by the same sponsor.
- NCT07370064 — Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · not yet recruiting
- NCT07280793 — CAR-T Cell Efficacy With Molecular Imaging in Multiple Myeloma · EARLY_PHASE1 · not yet recruiting
- NCT07070960 — A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible · NA · not yet recruiting
- NCT07070934 — CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients? · Phase 2 · not yet recruiting
- NCT06963866 — Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05782764 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuzhou Medical University
- Last refreshed: 24 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05782764.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing